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these poABs to compete for the binding of fluid phase neoepitope 
fragments with solid phase ovalbumin linked synthetic peptides. 
The solid phase complex is detected with peroxidase conjugated 
anti-rabbit IgG. These competitive ELISAs have nM sensitivity as 
determined by spike recovery of synthetic peptide in the assay 
buffer. Neoepitope specific ELISA assays will enable the quanti- 
tative evaluation of neoepitope containing aggrecan fragments in 
response to disease progression and therapeutic intervention. 
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Aim: To measure the levels of aggrecanase (ADAMTS)- 
generated aggrecan AGG-C1 neoepitope (G1-TEGE 373) in bio- 
logical fluids from a preclinical model of osteoarthritis (OA), and 
determine its utility as a correlative biomarker for disease pro- 
gression. 
Methods: A preclinical model of OA was propagated following 
anterior cruciate ligament ransection (ACLT) in rabbit hind-limbs, 
and biological fluid samples (i.e. serum, synovial fluid, urine) were 
collected at various time points post-surgery. Samples from age- 
matched control (unoperated) animals were similarly harvested. 
Monoclonal antibody AGG-C1 (which specifically recognizes the 
aggrecanase-generated catabolic neoepitope ... TEGE 373) was 
utilized in a competitive ELISA format to assay biological fluids. 
Results: AGG-C1 neoepitope was readily detectable in synovial 
fluid and serum samples, wherein its levels were elevated longi- 
tudinally following ACLT surgery. 
Conclusions: During the course of degenerative joint diseases 
such as OA, ADAMTS (aggrecanase)-mediated aggrecanoly- 
sis contributes ignificantly to cartilage proteoglycan depletion, 
and ultimate tissue destruction. Specifically, cleavage of the 
aggrecanase-susceptible E373-A 374 bond within the interglobular 
domain causes the detrimental loss of sGAG-rich aggrecan frag- 
ments, thereby compromising the biomechanical competence of 
the articular cartilage. Concordantly, aggrecanase-generated G1
domains (G1-TEGE 373) are also released from cartilage into the 
synovial fluid. In the present study, we have demonstrated the 
utility of neoepitope-specific monoclonal antibody AGG-C1 (anti- 
TEGE 373) in a preclinical biomarker assay for OA progression, us- 
ing accessible biological fluids such as peripheral blood (serum), 
wherein the AGG-C1 neoepitope persists. 
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Aim: ADAMTS-4 and ADAMTS-5 are known to cleave aggre- 
can, the major articular cartilage proteoglycan, at various sites 
along the molecule. This results in the release of aggrecan frag- 
ments into synovial fluid which contain the aggrecan neoepi- 
tope NITEGE and the glycosaminoglycan, chondroitin sulphate 
(CS). We have used this information to develop two pharmaco- 
dynamic assays to test ADAMTS-4/5 inhibitors in vivo. Aggrecan 
degradation is induced by the intra-articular injection of recom- 
binant ADAMTS-4 or ADAMTS-5 followed by detection of aggre- 
can catabolism with either a direct ELISA based on an antibody 
to a CS epitope or a sandwich ELISA utilizing antibodies to both 
the NITEGE neoepitope and the HABR (aggrecan hyaluronic acid 
binding region). 
Method: Male Lewis rats are anaesthetized and injected intra- 
articularly with varying concentrations of either recombinant 
ADAMTS-4 or ADAMTS-5 dissolved in 50ul of buffer. The con- 
tralateral knee is injected with buffer alone as a control. One 
hour after injection of enzyme the knees are lavaged with 200ul 
of saline and the synovial lavage assayed for CS and NITEGE 
content. Lavage fluid is measured for CS by an ELISA which 
uses mouse monoclonal antibody CS56 that recognizes CS and 
for NITEGE with a sandwich ELISA which uses antibodies to 
hyaluronic binding region (HABR) of aggrecan and the NITEGE 
neoepitope. MMP-13 (2.5ug per knee) was used as a specificity 
control for the NITEGE-HABR ELISA. 
To test ADAMTS-4/5 inhibitory activity of com pounds in this assay 
we used two broad-spectrum MMP inhibitors (Marimastat, British 
Biotech and Ro130830, Roche Bioscience) that also have some 
activity against ADAMTS-4 and ADAMTS-5: Marimastat IC50 22 
nM and 80 nM; Ro 130830 Marimastat IC50 200 nM and 56 nM 
respectively. IC50's were determined from an alpha screen assay 
for aggrecanases using a synthetic 43mer peptide as substrate. 
The compounds were dosed at 50mg/kg po one hour before in- 
jection of enzyme. Plasma was taken one hour after enzyme in- 
jection and assayed for MMP activity to confirm the presence of 
compound. 
Results: Both ADAMTS-4 and ADAMTS-5 at 10ug per knee were 
able to degrade rat knee cartilage aggrecan in vivo as measured 
by the release of CS and the NITEGE neoepitope. Levels of CS 
and NITEGE in synovial lavage were at least 10 fold higher than 
those seen with buffer alone. No NITEGE fragments were de- 
tected in MMP-13 injected knees. 
Marimastat was the most potent compound at inhibiting 
ADAMTS-4 (CS ELISA 60% and NITEGE-HABR ELISA 70%) 
and Ro130830 most potent for ADAMTS-5 (CS ELISA 60% and 
NITEGE-HABR ELISA 60%). The plasma assay for MMP activity 
showed complete inhibition of enzymatic activity. 
Discussion: Both ADAMTS-4 and ADAMTS-5 were able to de- 
grade aggrecan after intra-articular injection as measured by 
chondrotin sulphate and NITEGE-HABR ELISAs. This degrada- 
tion of aggrecan can be inhibited by reference compounds con- 
firming we have a pharmacodynamic assay for testing potential 
ADAMTS-4/5 inhibitors in vivo. 
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Aim of Study: The human MMP-13 plays a major role in normal 
cartilage remodeling and osteoarthritic (OA) processes. We pre- 
viously identified the regulatory site AGRE (GAAAA GAAAAAG) 
in the proximal promoter of this gene. Electrophoretic mobility 
shift assays (EMSA) done with nuclear extracts from OA chon- 
drocytes showed the presence of two AGRE-protein binding com- 
plexes, which depended on the pathophysiological state of the 
cells. In this study, we further investigated whether each AGRE 
